CELLDEX THERAPEUTICS INC (CLDX) Stock Price, Quote, News and Summary
NASDAQ:CLDX - Nasdaq - US15117B2025 - Common Stock
CLDX Quote and Key Statistics
CELLDEX THERAPEUTICS INC
NASDAQ:CLDX (1/21/2025, 8:00:00 PM)
After market: 24.61 0 (0%)24.61
+0.83 (+3.49%)
CLDX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.72% | ||
| ROE | -19.61% | ||
| Debt/Equity | 0 |
CLDX Performance and Technical Analysis
CLDX Ownership and Analysts
CLDX Latest News and Analysis
These stocks are moving in today's after hours session
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Interesting CLDX Put And Call Options For March 21st
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study...
About CLDX
Company Profile
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 160 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Company Info
CELLDEX THERAPEUTICS INC
53 Frontage Road, Suite 220
Hampton NEW JERSEY 08827 US
CEO: Anthony S. Marucci
Employees: 160
Company Website: https://celldex.com/
Investor Relations: https://ir.celldex.com
Phone: 19082007500
CLDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |